MPN_Hub

Preliminary data from the phase II ODYSSEY trial of momelotinib + luspatercept in transfusion dependent #myelofibrosis show the majority of patients (64%) achieved stabilized or reduced transfusion burden vs baseline. Learn more: bit.ly/4uoZrlQ #MPN #MPNsm #MedNews #MedEd

New publication 📝 RUX‑MF subanalysis results, published in Cancer, show that patients treated with ruxolitinib who were never cytopenic demonstrated longer median OS vs patients with persistent cytopenia (8.07 years vs 3.68 years; p < 0.001). Learn more about MF: bit.ly/4snWHUc #myelofibrosis #MPN #MedNews #MedEd

New publication 📝 Results from a nationwide Swedish cohort study, published in the European Journal of Haematology, show that the risk of AML/MDS transformation in PV, ET, and PMF varies by attained age and disease duration. Learn more: bit.ly/4acXNKD #MPN #MPNsm #MedNews #MedEd

New publication 📝 Results from a retrospective, multi-institutional study, published in @LeukemiaJnl, show an AI model achieved 92.3% accuracy in distinguishing prePMF from ET using bone marrow biopsy images. Learn more about MPN: bit.ly/4acXNKD #MPN #MedNews #MedEd

What is your initial treatment approach for a patient presenting with anemia and myelofibrosis at diagnosis who requires a JAK inhibitor (JAKi)?

Preliminary data from the phase II ODYSSEY trial of momelotinib + luspatercept in transfusion dependent #myelofibrosis show the majority of patients (64%) achieved stabilized or reduced transfusion burden vs baseline. Learn more: bit.ly/4uoZrlQ #MPN #MPNsm #MedNews #MedEd

New publication 📝 Survey data, published in the Journal of Cancer Research and Clinical Oncology, show 51.8% of patients with BCR::ABL1-negative MPN use complementary and alternative medicine, with higher usage among females vs males (59.6% vs 41.7%; p = 0.022). Learn more: bit.ly/4acXNKD #MPN #MPNsm #MedNews #MedEd

New publication 📝 Discover the rationale for the phase II ODYSSEY trial of momelotinib + luspatercept in transfusion dependent #myelofibrosis, and key data from the preliminary analysis. Learn more: bit.ly/4uoZrlQ #MPN #MPNsm #MedNews #MedEd

📝 Stay ahead of the latest medical news in #MPN! Get the latest trial data, therapy breakthroughs, and expert insights delivered straight to your inbox. Sign up for the MPN Hub newsletter today: bit.ly/4aJmYGf #mpnsm #MedEd #MedTwitter

New publication 📝 Pharmacokinetic data, published in @BloodPortfolio, show ropeginterferon alfa‑2b has negligible placental transfer and minimal breast milk secretion in pregnant/lactating patients with MPN. Learn more about MPN: bit.ly/4acXNKD #MPNsm #MedNews #MedEd

🚨NEWS🚨 @US_FDA accepts NDA and grants priority review for rusfertide, a hepcidin mimetic peptide, for the treatment of PV, based on results from the VERIFY, REVIVE, and THRIVE studies. Read more: bit.ly/3NjDaVO #MPNsm #MedEd #MedNews

New publication 📝 Findings from a single-center registry analysis, published in Hematology, support consideration of broader genomic profiling to improve molecular classification and inform longitudinal monitoring in #EssentialThrombocythemia. Learn more: bit.ly/4r08rei #MPN #MPNsm #MedNews #MedEd

New publication 📝 A retrospective study, published in Annals of Hematology, shows TSI, EPO, and JAK2 VAF may be useful diagnostic markers to differentiate between #PV and #ET. Learn more about MPN: bit.ly/4acXNKD #MPN #MedNews #MedEd

New publication 📝 Results from a retrospective validation study, published in @LeukemiaJnl, show anemia + thrombocytopenia has poor prognostic discrimination for 10-year survival in overt PMF (AUC, 0.52 in ERNEST-2 and 0.50 in Pavia-CSM). Learn more: bit.ly/4r5jPpY #MPN #MPNsm #MedNews #MedEd

New publication 📝 Phase II results, published in @BloodPortfolio, show ropeginterferon alfa‑2b HIDAT regimen achieved 34.9% CMR at 36 months in patients with HU-intolerant #PV. Learn more: bit.ly/4a7J9Wu #MPNsm #MedNews #MedEd

New publication 📝 Observational findings, published in Annals of Hematology, show that NLR ≥6 at diagnosis independently predicts venous thrombosis in prePMF (HR, 3.82; 95% CI, 1.42–10.29). Learn more: bit.ly/4rmN3B1 #MPN #MPNsm #MedNews #MedEd

New publication 📝 Observational data, published in Annals of Hematology, show higher ORR to luspatercept in patients with MPN or MDS/MPN and SF3B1 mutations vs patients with wild-type SF3B1 (83.3% vs 36.8%; p = 0.012). Learn more: bit.ly/4acXNKD #MPN #MedNews #MedEd

New publication📝 Multicenter retrospective cohort study, published in @BloodPortfolio, shows statin use was associated with reduced risk of MACE in patients with MPN (SHR, 0.83), particularly ET or PV (SHR, 0.78); but not with disease progression or ACM. Learn more: bit.ly/4acXNKD #MPN #MPNsm #MedNews #MedEd

Combination regimens including BCMA-directed therapies are an ongoing area of investigation, aiming to improve responses and address resistance mechanisms in #MultipleMyeloma. Watch the full video here: bit.ly/3ZySNey #myeloma #mmsm #MedEd @MVMateos

New publication 📝 MPN-FIT results, published in @BloodPortfolio, show that supervised exercise significantly improves QoL for MPN patients, with 92% intending to continue regular physical activity post-study. Learn more: bit.ly/4acXNKD #MPN #MedNews #MedEd